[go: up one dir, main page]

CL2010001634A1 - Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. - Google Patents

Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.

Info

Publication number
CL2010001634A1
CL2010001634A1 CL2010001634A CL2010001634A CL2010001634A1 CL 2010001634 A1 CL2010001634 A1 CL 2010001634A1 CL 2010001634 A CL2010001634 A CL 2010001634A CL 2010001634 A CL2010001634 A CL 2010001634A CL 2010001634 A1 CL2010001634 A1 CL 2010001634A1
Authority
CL
Chile
Prior art keywords
nucleosides
hepatitis
preparation procedure
compounds derived
pharmaceutical composition
Prior art date
Application number
CL2010001634A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Original Assignee
Centocor Ortho Biotech Products L P
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010001634(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Products L P, Medivir Ab filed Critical Centocor Ortho Biotech Products L P
Publication of CL2010001634A1 publication Critical patent/CL2010001634A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de nucleósidos, inhibidores del virus de la hepatitis C; procedimiento de preparación; composición farmacéutica que los comprende; y combinación farmacéutica.
CL2010001634A 2008-07-01 2010-12-30 Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica. CL2010001634A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08

Publications (1)

Publication Number Publication Date
CL2010001634A1 true CL2010001634A1 (es) 2011-08-05

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001634A CL2010001634A1 (es) 2008-07-01 2010-12-30 Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.

Country Status (29)

Country Link
US (1) US8431588B2 (es)
EP (1) EP2141172B1 (es)
JP (1) JP5624029B2 (es)
KR (1) KR20110038683A (es)
CN (2) CN105693794A (es)
AP (1) AP2010005505A0 (es)
AR (1) AR072428A1 (es)
AU (1) AU2009266004B2 (es)
BR (1) BRPI0913643A2 (es)
CA (1) CA2729316A1 (es)
CL (1) CL2010001634A1 (es)
CO (1) CO6321255A2 (es)
DK (1) DK2141172T3 (es)
EA (1) EA022754B1 (es)
EC (1) ECSP10010725A (es)
ES (1) ES2396803T3 (es)
HK (1) HK1226080A1 (es)
HR (1) HRP20121068T1 (es)
IL (1) IL209932A (es)
MX (1) MX2010014493A (es)
NI (1) NI201000231A (es)
PL (1) PL2141172T3 (es)
PT (1) PT2141172E (es)
SI (1) SI2141172T1 (es)
SV (1) SV2010003779A (es)
TW (1) TW201012814A (es)
UY (1) UY31950A (es)
WO (1) WO2010000459A1 (es)
ZA (1) ZA201009294B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193820A1 (en) * 2008-09-08 2013-10-30 Novomer Inc Polycarbonate polyol compositions and methods
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
PE20140039A1 (es) 2010-12-30 2014-03-01 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
KR20140129019A (ko) 2012-02-14 2014-11-06 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 플라비비리다에 감염의 치료를 위한 스피로[2.4]헵탄
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
RU2764767C2 (ru) 2015-03-06 2022-01-21 Атеа Фармасьютикалс, Инк. β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
CN116036114A (zh) 2016-09-07 2023-05-02 阿堤亚制药公司 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
CA3048033C (en) 2017-02-01 2023-06-20 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331643T2 (de) 1992-12-29 2002-10-31 Abbott Laboratories, Abbott Park Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
CN104193791A (zh) * 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
CA2523083C (en) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
JP2008510748A (ja) * 2004-08-23 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４’−アジド−ヌクレオシド
CN101979397B (zh) * 2006-10-10 2013-11-06 美迪维尔公司 Hcv核苷类抑制剂

Also Published As

Publication number Publication date
TW201012814A (en) 2010-04-01
WO2010000459A1 (en) 2010-01-07
US20110092460A1 (en) 2011-04-21
HRP20121068T1 (hr) 2013-01-31
KR20110038683A (ko) 2011-04-14
US8431588B2 (en) 2013-04-30
CA2729316A1 (en) 2010-01-07
PT2141172E (pt) 2013-01-14
EP2141172A1 (en) 2010-01-06
MX2010014493A (es) 2011-05-19
EA201170118A1 (ru) 2011-06-30
ZA201009294B (en) 2012-06-27
AU2009266004A1 (en) 2010-01-07
HK1226080A1 (zh) 2017-09-22
IL209932A0 (en) 2011-02-28
EA022754B1 (ru) 2016-02-29
ES2396803T3 (es) 2013-02-27
JP2011526270A (ja) 2011-10-06
NI201000231A (es) 2011-09-03
UY31950A (es) 2010-01-29
CN102083845B (zh) 2016-09-14
AU2009266004B2 (en) 2014-01-30
CO6321255A2 (es) 2011-09-20
ECSP10010725A (es) 2011-04-29
IL209932A (en) 2013-12-31
SV2010003779A (es) 2011-02-08
JP5624029B2 (ja) 2014-11-12
AP2010005505A0 (en) 2010-12-31
AR072428A1 (es) 2010-08-25
CN102083845A (zh) 2011-06-01
DK2141172T3 (da) 2013-01-21
CN105693794A (zh) 2016-06-22
PL2141172T3 (pl) 2013-03-29
SI2141172T1 (sl) 2013-02-28
BRPI0913643A2 (pt) 2015-11-24
EP2141172B1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
DOP2013000185A (es) Compuestos antivirales
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CO6761348A2 (es) Compuestos antivirales
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
EA201190013A1 (ru) Ингибиторы ns5a вгс
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CL2011001224A1 (es) Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
ECSP10010004A (es) Derivados de indol 2-carboxi sustituidos y métodos para su utilización
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EA201170227A1 (ru) Имидазолкарбоксамиды
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.